Literature DB >> 11461154

Identification of the full-length huntingtin- interacting protein p231HBP/HYPB as a DNA-binding factor.

S Rega1, T Stiewe, D I Chang, B Pollmeier, H Esche, W Bardenheuer, G Marquitan, B M Pützer.   

Abstract

Neurodegeneration in Huntington's disease (HD) is associated with an elongated glutamine tract in the widely expressed huntingtin protein. Although the pathogenic mechanisms are still unknown, the distinct physical properties of mutant huntingtin in the brain suggest that other factors including huntingtin-interacting proteins might play a specific role. We have previously identified a DNA-binding motif in the proximal E1A promoter of adenovirus serotype 12 as responsible for E1A autoregulation. Here, we identified the p231HBP protein as a DNA-binding factor, the C-terminal portion of which has recently been characterized as the huntingtin-interacting protein HYPB of unknown function. We have determined the full-length cDNA sequence, identified several domains supporting its gene regulatory functions, and mapped the HBP231 gene to chromosome 3p21.2-p21.3. Our results provide an interesting molecular link between huntingtin and a DNA-binding factor, implicating that this interaction might result in the alteration of cellular gene expression involved in HD pathogenesis. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11461154     DOI: 10.1006/mcne.2001.1004

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  10 in total

Review 1.  Pathological implications of nucleic acid interactions with proteins associated with neurodegenerative diseases.

Authors:  Yraima Cordeiro; Bruno Macedo; Jerson L Silva; Mariana P B Gomes
Journal:  Biophys Rev       Date:  2014-01-09

2.  Modifications of p53 and the DNA damage response in cells expressing mutant form of the protein huntingtin.

Authors:  Jennifer L Illuzzi; Cassie A Vickers; Eric B Kmiec
Journal:  J Mol Neurosci       Date:  2011-04-05       Impact factor: 3.444

3.  Proteomics of dense core secretory vesicles reveal distinct protein categories for secretion of neuroeffectors for cell-cell communication.

Authors:  Jill L Wegrzyn; Steven J Bark; Lydiane Funkelstein; Charles Mosier; Angel Yap; Parsa Kazemi-Esfarjani; Albert R La Spada; Christina Sigurdson; Daniel T O'Connor; Vivian Hook
Journal:  J Proteome Res       Date:  2010-10-01       Impact factor: 4.466

4.  Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner.

Authors:  Caroline L Benn; Tingting Sun; Ghazaleh Sadri-Vakili; Karen N McFarland; Derek P DiRocco; George J Yohrling; Timothy W Clark; Bérengère Bouzou; Jang-Ho J Cha
Journal:  J Neurosci       Date:  2008-10-15       Impact factor: 6.167

5.  miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.

Authors:  Wei Xiang; Jun He; Chao Huang; Lejun Chen; Dan Tao; Xinchao Wu; Miao Wang; Gang Luo; Xingyuan Xiao; Fuqing Zeng; Guosong Jiang
Journal:  Oncotarget       Date:  2015-02-28

6.  LncRNA HOTAIR promotes human liver cancer stem cell malignant growth through downregulation of SETD2.

Authors:  Haiyan Li; Jiahui An; Mengying Wu; Qidi Zheng; Xin Gui; Tianming Li; Hu Pu; Dongdong Lu
Journal:  Oncotarget       Date:  2015-09-29

7.  Identification of SETD2-NF1 fusion gene in a pediatric spindle cell tumor with the chromosomal translocation t(3;17)(p21;q12).

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Ingvild Lobmaier; Bodil Bjerkehagen; Sverre Heim
Journal:  Oncol Rep       Date:  2017-05-04       Impact factor: 3.906

8.  Mutant Huntingtin Protein Interaction Map Implicates Dysregulation of Multiple Cellular Pathways in Neurodegeneration of Huntington's Disease.

Authors:  Sonia Podvin; Sara Brin Rosenthal; William Poon; Enlin Wei; Kathleen M Fisch; Vivian Hook
Journal:  J Huntingtons Dis       Date:  2022

9.  The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters.

Authors:  W Al Sarakbi; W Sasi; W G Jiang; T Roberts; R F Newbold; K Mokbel
Journal:  BMC Cancer       Date:  2009-08-21       Impact factor: 4.430

Review 10.  SETD2: an epigenetic modifier with tumor suppressor functionality.

Authors:  Jun Li; Gerben Duns; Helga Westers; Rolf Sijmons; Anke van den Berg; Klaas Kok
Journal:  Oncotarget       Date:  2016-08-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.